- Home
- ADMA
ADMA
ADMA Biologics Inc
as 11-22-2024 4:00pm EST
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | RAMSEY |
| Market Cap: | 5.3B | IPO Year: | N/A |
| Target Price: | $21.25 | AVG Volume (30 days): | 3.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.60 - $23.64 | Next Earning Date: | 11-07-2024 |
| Revenue: | $382,809,000 | Revenue Growth: | 63.39% |
| Revenue Growth (this year): | 60.41% | Revenue Growth (next year): | 13.09% |
Stock Insider Trading Activity of ADMA Biologics Inc (ADMA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Guiheen Lawrence P. | ADMA | Director | Sep 9 '24 | Sell | $18.47 | 9,000 | $166,188.60 | 153,941 | |
| Kestenberg-Messina Kaitlin M. | ADMA | COO and SVP, Compliance | Aug 30 '24 | Sell | $16.90 | 24,150 | $408,050.48 | 449,088 | |
| Grossman Jerrold B | ADMA | Director | Aug 29 '24 | Sell | $17.27 | 136,861 | $2,363,931.62 | 467,305 | |
| Grossman Adam S | ADMA | President and CEO | Aug 26 '24 | Sell | $17.49 | 626,245 | $10,923,987.26 | 2,059,726 |
Latest ADMA Biologics Inc News
ADMA Breaking Stock News: Dive into ADMA Ticker-Specific Updates for Smart Investing
Zacks
6 days ago
Wall Street Analysts See a 31.3% Upside in Adma Biologics (ADMA): Can the Stock Really Move This High?
Zacks
9 days ago
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
Simply Wall St.
9 days ago
Statutory Profit Doesn't Reflect How Good ADMA Biologics' (NASDAQ:ADMA) Earnings Are
Argus Research
11 days ago
ADMA: Raising target price to $26.00
Zacks
12 days ago
ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?
Investor's Business Daily
12 days ago
Vericel Stock Sees RS Rating Shoot Higher
Zacks
13 days ago
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?
Simply Wall St.
15 days ago
Earnings Beat: Here's What ADMA Biologics, Inc. (NASDAQ:ADMA) Analysts Are Forecasting For Next Year
Compare ADMA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADMA ADMA Biologics Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.